Skip to main content
Have a personal or library account? Click to login
Hemolymphoreticular Neoplasias from the Ramazzini Institute Long-term Mice and Rat Studies on Aspartame Cover

Hemolymphoreticular Neoplasias from the Ramazzini Institute Long-term Mice and Rat Studies on Aspartame

Open Access
|Jun 2023

References

  1. Soffritti M, Belpoggi F, Esposti DD, Lambertini L, Tibaldi E, Rigano A. First experimental demonstration of the multipotential carcinogenic effects of aspartame administered in the feed to Sprague-Dawley rats. Environ Health Perspect. 2006; 114(3): 379385. DOI: 10.1289/ehp.8711
  2. Soffritti M, Belpoggi F, Tibaldi E, Esposti DD, Lauriola M. Life-span exposure to low doses of aspartame beginning during prenatal life increases cancer effects in rats. Environl Health Perspect. 2007; 115(9): 12931297. DOI: 10.1289/ehp.10271
  3. Soffritti M, Belpoggi F, Manservigi M, et al. Aspartame administered in feed, beginning prenatally through life span, induces cancers of the liver and lung in male Swiss mice. Am J of Indl Med. 2010; 53(12): 11971206. DOI: 10.1002/ajim.20896
  4. Tibaldi E, Gnudi F, Panzacchi S, et al. Identification of aspartame-induced haematopoietic and lymphoid tumours in rats after lifetime treatment. Acta Histochemica. 2020; 122(5): 151548. DOI: 10.1016/j.acthis.2020.151548
  5. Landrigan PJ, Straif K. Aspartame and cancer – new evidence for causation. Environ Health. 2021; 20(1): 42. DOI: 10.1186/s12940-021-00725-y
  6. Willard-Mack CL, Elmore SA, Hall WC, et al. Nonproliferative and proliferative lesions of the rat and mouse hematolymphoid system. Toxicologic pathology. 2019; 47(6): 665783. DOI: 10.1177/0192623319867053
  7. Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, (eds.) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues; 2017. WHO series on histological and genetic typing of human tumours; vol 2. 4th edition. International Agency for Research on Cancer.
  8. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022; 36(7): 17201748. DOI: 10.1038/s41375-022-01620-2
  9. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022; 36(7): 17031719. DOI: 10.1038/s41375-022-01613-1
  10. Falcioni L, Bua L, Tibaldi E, et al. Report of final results regarding brain and heart tumours in Sprague-Dawley rats exposed from prenatal life until natural death to mobile phone radiofrequency field representative of a 1.8 GHz GSM base station environmental emission. Environ Res. 2018; 165: 496503. DOI: 10.1016/j.envres.2018.01.037
  11. Bua L, Tibaldi E, Falcioni L, et al. Results of lifespan exposure to continuous and intermittent extremely low frequency electromagnetic fields (ELFEMF) administered alone to Sprague Dawley rats. Environ Res. 2018; 164: 271279. DOI: 10.1016/j.envres.2018.02.036
  12. OECD. Test No. 451: Carcinogenicity Studies. OECD Guidelines for the Testing of Chemicals, Section 4. OECD Publishing; 2018.
  13. OECD. Guidance Document 116 on the Conduct and Design of Chronic Toxicity and Carcinogenicity Studies, Supporting Test Guidelines 451, 452 and 453. OECD Series on Testing and Assessment. No 116. 2nd Edition. OECD Publishing; 2014.
  14. Gart J, Krewski D, Lee P, Tarone R, Wahrendorf J. Statistical methods in cancer research. Volume III--The design and analysis of long-term animal experiments. IARC Sci Pub. 1986; (79): 1219.
DOI: https://doi.org/10.5334/aogh.4163 | Journal eISSN: 2214-9996
Language: English
Submitted on: May 3, 2022
Accepted on: May 26, 2023
Published on: Jun 20, 2023
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2023 Federica Gnudi, Simona Panzacchi, Eva Tibaldi, Martina Iuliani, Daria Sgargi, Luciano Bua, Daniele Mandrioli, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.